It’s Time for Sites to “Bring Your Own Technology” (BYOT)
Sites gain control with Advarra’s BYOT approach, eliminating redundant tasks and fostering efficient collaboration between research stakeholders and participants.
sponsors
Critical Steps for Writing an Impactful Clinical Audit Report
The amount of detail required in an audit may vary – ranging from an executive, high-level summary with detailed observations,
The Advantages of Outsourcing IRB and IBC Reviews to One Partner
Gene therapy studies are a relatively recent addition to the world of clinical research. As a result, the unique requirements
Understanding Various Decentralized Terms in Research
As many research organizations are becoming more patient-centric and adapting to technological advancements and remote requirements, they are re-designing the
Navigating the FDA Emergency Use Filing Process
In an effort to create safe, effective, and affordable ventilators to help combat the foreseeable shortages due to COVID-19, one
Improving Patient Centricity and Research Access
A clinical research trial can only be as strong its participant population, but it’s challenging to find eligible patients.
For FDA Inspection Readiness, Accountability is Key
Dawn Wydner, former Food and Drug Administration (FDA) Consumer Safety Officer, LCDR, and current Managing Expert for Advarra’s Quality Center
Top 10 Educational Resources of 2021
The year 2021 brought many advancements in the clinical research industry. We’ve pushed for more diversity and inclusion in clinical
Q&A: FDA Updates: BIMO – What Sponsors Need to Know
Advarra experts Joan Versaggi and Leslie Paul answer questions from the first in the webinar series – FDA Updates: BIMO
The Key to Increasing Diversity in Decentralized Trials
Historically, decentralized clinical trials (DCTs) were heralded as the future of patient-centered research. But how can your organization “walk the
Unique Ethical Issues in Phase I Oncology Studies
Phase I oncology trials present distinct ethical challenges, such as participant vulnerability and the risk of therapeutic misconception, requiring careful oversight.
Returning to In-person Work: Sponsor Versus Site Viewpoints
As March 2020 completely disrupted any sense of normalcy, including in the workplace, many were forced to adapt rather quickly.